Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination - Concepedia

Concepedia

Publication | Open Access

Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

DOI Full Paper Access

84

Citations

5

References

2022

Year

Marton König, Hilde Marie Torgauten, The Trung Tran, Trygve Holmøy, John Torgils Vaage, Fridtjof Lund‐Johansen, Gro Owren Nygaard

Abstract

This cohort study investigates the immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis who had a weak immune response to COVID-19 vaccination.

References

	Year	Citations

Page 1